Drug-drug interactions associated with FLT3 inhibitors for acute myeloblastic leukemia: current landscape.
Antonio Solana-AltabellaJuan Eduardo Megías-VericatOctavio Ballesta-LópezDavid Martínez-CuadrónPau MontesinosPublished in: Expert review of clinical pharmacology (2023)
FLT3i will be combined with other therapeutic agents (supportive care, doublet, or triplet therapy) and in different clinical settings, which means a greater chance of controlling and even eradicating the disease effectively, but also an increased risk to patients due to potential DDIs. Healthcare professionals should be aware of the potential interactions that may occur and be vigilant in monitoring those patients who are receiving any potentially interacting drug.
Keyphrases
- end stage renal disease
- acute myeloid leukemia
- ejection fraction
- chronic kidney disease
- healthcare
- prognostic factors
- peritoneal dialysis
- tyrosine kinase
- emergency department
- patient reported outcomes
- liver failure
- intensive care unit
- hepatitis b virus
- drug induced
- climate change
- mesenchymal stem cells
- quality improvement
- health insurance
- adverse drug
- acute respiratory distress syndrome
- mechanical ventilation